Life Technologies Launches Compendia Oncomine® NGS Power Tools for Cancer Researchers, Discovers Novel Gene Fusions

  Life Technologies Launches Compendia Oncomine® NGS Power Tools for Cancer
                  Researchers, Discovers Novel Gene Fusions

PR Newswire

CARLSBAD, Calif., June 10, 2013

CARLSBAD, Calif., June 10, 2013 /PRNewswire/ --Life Technologies Corporation
(NASDAQ: LIFE) announced today the introduction of Oncomine® Next Gen
Sequencing Power Tools, an analytics offering that will allow cancer
researchers to explore results from in-depth analysis of next generation
sequencing (NGS) data, including data from The Cancer Genome Atlas. In total,
more than 4,500 paired tumor and samples have been analyzed to date.

"NGS has significant potential to deliver insights into what drives cancers
and how the disease might be combated," saidDan Rhodes, Ph.D., head of
medical science informatics forLife Technologies. "However, the field has
only begun to take advantage of the enormous amounts of data becoming
available. The Oncomine NGS Power Tools provide simple access to comprehensive
findings, many of them novel, from a team with a proven track record of mining
scientific value from big data."

Oncomine® NGS Power Tools constitutes a suite of software tools that enable
cancer researchers to easily survey novel predicted driver mutations and gene
fusions across all cancers and within two dozen specific cancers types, as
well as explore simple summary analyses that integrate multiple types of gene
and pathway aberrations with clinical data.

In addition to basic research applications, the NGS tools also provide a
foundation for specialized biomarker services to pharma and biotech customers
in their efforts to evaluate NGS data for biomarker and companion diagnostic

With collaborators from the University of Michigan Medical School, Life
Technologies scientists used the NGS Power Tools to discover FGFR gene fusions
across a range of cancer types. These results are reported in the current
issue of Cancer Discovery.

The investigators discovered FGFR fusions across a highly diverse set of nine
distinct tumor types, including lung squamous cell cancer, bladder cancer,
thyroid cancer, oral cancer, glioblastoma, and head and neck squamous cell
cancer. Normal cell lines transfected with fusion constructs exhibited
enhanced growth that was sensitive to FGFR inhibitors, indicating that the
fusion genes were in fact acting to drive the cancers.

"We found that FGFR fusions occur across many more tumor types than has been
previously reported," said Rhodes. "As a number of clinical trials for FGFR
inhibitors are underway, these data underscore the importance of conducting
trials based on mutation profiles rather than tissue of origin."

"Life Tech's Oncomine NGS Tools provide access to a substantial collection of
results from NGS analysis, not available from any other source," said Dan
Robinson, Ph.D., assistant research professor at the Michigan Center for
Translational Pathology, University of Michigan Medical School. "With early
access, we were able to expand our conclusions on the importance of targeting
FGFR gene fusions in human cancer."

The new Oncomine® offering extends the Power Tools product line, which
includes Oncomine® Mutation Browser, Copy Number Browser, and Gene Expression
Browser, all containing data from both sequencing and microarray studies and
utilized by pharmaceutical companies in their drug discovery and development
work. In addition to products serving the pharmaceutical industry, Life
Technologies recently launched the Oncomine® Gene Browser for the academic and
smaller biotech market. The Gene Browser provides a comprehensive gene summary
at a moderate price point and is ideal for researchers working with small
numbers of genes.

The Oncomine® product line was initially developed by Compendia Bioscience,
which was acquired by Life Technologies in October, 2012.

AboutLife Technologies

Life Technologies Corporation(NASDAQ:LIFE) is a global biotechnology company
that is committed to providing the most innovative products and services to
leading customers in the fields of scientific research, genetic analysis and
applied sciences. With a presence in more than 180 countries, the company's
portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents
and licenses that span the entire biological spectrum -- scientific
exploration, molecular diagnostics, 21^stcentury forensics, regenerative
medicine and agricultural research.Life Technologieshas approximately 10,000
employees and had sales of$3.8 billionin 2012.

Life Technologies' Safe Harbor Statement

This press release includes forward-looking statements aboutLife
Technologies' anticipated results that involve risks and uncertainties. Some
of the information contained in this press release, including, but not limited
to, statements as to industry trends andLife Technologies' plans, objectives,
expectations and strategy for its business, contains forward-looking
statements that are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or implied by such
forward-looking statements. Any statements that are not statements of
historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and
the like, and/or future tense or conditional constructions ("will," "may,"
"could," "should," etc.), or similar expressions, identify certain of these
forward-looking statements. Important factors which could cause actual results
to differ materially from those in the forward-looking statements are detailed
in filings made byLife Technologies with theSecurities and Exchange
Commission.Life Technologies undertakes no obligation to update or revise any
such forward-looking statements to reflect subsequent events or circumstances.


Life Technologies Contact:

Suzanne Clancy
858-205-4235 (mobile)

SOURCE Life Technologies Corporation

Press spacebar to pause and continue. Press esc to stop.